Latest Headlines

Latest Headlines

Scripps, Scanadu finalize 4K+ vital sign trial enrollment, FDA-ready data due in 2016

Hand-held vital sign monitor Scanadu has made a big splash with its Indiegogo crowdfunding campaign that was followed up by being selected as a finalist in the $10 million Qualcomm Tricorder Xprize competition last year. Now it's working to legitimize its Scanadu Scout wireless vital sign monitor in a massive trial of more than 4,000 people conducted by Scripps Translational Science Institute.

Unilife attracts potential bidder, hires Morgan Stanley to review strategic alternatives

Unilife gained on acquisition speculation after a Sept. 2 disclosure that it has received interest from a potential acquirer and will start a process to review its options. The micro-cap has seen its share price tick up, but its valuation remains at only about $175 million.

AMRI signs on to help Saneca develop opium-based drugs

Contract drugmaker AMRI signed a deal with Italy's Saneca Pharmaceuticals to collaborate on opium-derived treatments, pairing up with eyes on the U.S. market for controlled substances.

Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan

Just in time for flu season, AstraZeneca granted Daiichi Sankyo an exclusive license to market its FluMist Quadrivalent in Japan. The live attenuated vaccine, delivered nasally, went through Phase III trials in Japanese children, and a regulatory submission is being prepared for Japan.

Celyad set to scale up China-focused R&D activities after linking with Medisun

Cell therapy specialist Celyad is set to add Hong Kong to the clinical trial program of its ischemic heart failure treatment, giving its newly recruited partner Medisun data to support an attempt to crack the potentially lucrative Chinese market.

China's Jiangsu Hengrui on a roll with $795M potential licensing deal with Incyte

China's Jiangsu Hengrui Medicine signed a deal with U.S.-based Incyte that could be worth as much as $795 million with milestones to outlicense rights outside of Greater China for its clinical-stage anti-PD-1 monoclonal antibody candidate, the latest of a string of deals in the past few months.

BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhII

Last week saw two developments by players large and small in a universal flu vaccine race that's heating up. Now, Israel-based BiondVax is following up with some news of its own: It's partnering with the National Institute of Allergy and Infectious Diseases to test its candidate in the U.S.

Shire and Sangamo break up their gene-editing partnership

Shire and Sangamo Biosciences are going their separate ways after three-plus years of collaboration in gene editing, with each company hanging on to the programs best aligned to its goals.

FDA partners with nonprofit device incubator Fogarty Institute to improve approval efficiency

The U.S. Food and Drug Administration and the Fogarty Institute for Innovation, one of the more prominent medical device incubators, have developed a new educational program designed to improve collaboration between medical device innovators and the FDA that's expected to make the device approval process more efficient.

HK's Medisun, Belgium's Celyad revise C-Cure pact for Greater China

Hong Kong's Medisun International and Belgium-based cell therapy company Celyad said the terms of a collaboration for Greater China registration and distribution of C-Cure have changed from a June 2014 deal that saw €25 million raised through the sale of shares to Medisun and a joint venture formed.